Skip to main content

Table 3 Baseline characteristics

From: Glycoprotein IIb/IIIa inhibitors for cardiogenic shock complicating acute myocardial infarction: a systematic review, meta-analysis, and meta-regression

Analysis GPI Standard treatment MD 95% CI P value I2 (%)
Age 66.6 ± 12.6 69.1 ± 12.3 − 2.75 − 0.64 to 0.83 0.13 74
LVEF 35 ± 9 32 ± 10 0.33 − 1.83 to 2.49 0.63 27
Analysis GPI Standard treatment OR 95% CI P value I2 (%)
Gender (male)* 470/640 258/397 1.43 1.09–1.89 0.01 8
Diabetes mellitus 112/470 90/306 0.77 0.55–1.08 0.13 0
Hypertension* 247/425 168/225 0.68 0.49–0.94 0.02 74
Tobacco use* 197/470 87/306 1.87 1.20–2.91 0.006 36
Previous MI 82/470 77/306 0.75 0.48–1.18 0.21 25
3 vessel disease 181/425 124/225 0.64 0.29–1.45 0.29 79
Left main lesion 74/446 31/298 1.54 0.52–4.57 0.44 76
Invasive ventilation 312/586 198/338 1.20 0.62–2.23 0.57 65
IABP 363/640 149/397 2.13 0.96–4.72 0.06 82
TIMI 0/1 pre-procedure 167/595 185/346 0.60 0.19–1.88 0.38 90
  1. Bernat et al.’s study did not provide information regarding baseline data and was therefore not included in the baseline characteristics analysis
  2. GPI glicoprotein IIb/IIIa inhibitors, MD mean difference, CI confidence intervals, OR odds ratio, LVEF left ventricular ejection fraction, MI myocardial infarction, IABP intraortic balloon pump, TIMI thrombolysis in myocardial infarction